Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call Transcript
02:45pm, Friday, 06'th Nov 2020
Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call Transcript
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
04:35pm, Thursday, 05'th Nov 2020
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic g
American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL
09:18am, Wednesday, 04'th Nov 2020
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Cellectis (CLLS) Investor Presentation - Slideshow
10:54am, Friday, 11'th Sep 2020
The following slide deck was published by Cellectis S.A. in conjunction with this event..
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
01:24pm, Tuesday, 25'th Aug 2020
Over a dozen regenerative medicine drugs have been launched, generating revenues approaching $4 billion in 2019.
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020
08:30pm, Wednesday, 05'th Aug 2020
* Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in r/r B-ALL patients * Enrollment ongoing in Phase 1 dose-escalation trial AMELI-01 in r/r AML patients * MELANI-01 trial in r
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT
08:30pm, Wednesday, 29'th Jul 2020
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allo
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing
08:30pm, Tuesday, 21'st Jul 2020
NEW YORK, July 21, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on.
Monthly information on share capital and company voting rights
10:04pm, Friday, 10'th Jul 2020
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, July 10, 2020 -- Listing market: Euronext Growth ISIN code: FR0010425595.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * Akero
To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors
09:19pm, Monday, 06'th Jul 2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) - André Choulika, Ph.D., Cellectis’ Chairman and CEO, announces that he will focus all his energy on Cellectis’ development activities, and thus,
Cellectis Reports Clinical Hold Placed on MELANI-01 Study
08:33pm, Monday, 06'th Jul 2020
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELAN
Cellectis SA (CLLS): Hedge Funds Are Snapping Up
02:28am, Monday, 06'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?
03:30pm, Tuesday, 30'th Jun 2020
Is (CLLS) Outperforming Other Medical Stocks This Year?
